The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes
Andrew D. Graustein(University of Washington), Thomas R. Hawn(University of Washington), Willem A. Hanekom(Africa Health Research Institute), Muki Shey(University of Cape Town), Nguyễn Thụy Thương Thương(University of Oxford), Takashi Angata(Institute of Biological Chemistry, Academia Sinica), Heather C. Mefford(St. Jude Children's Research Hospital), Ajit Varki(University of California San Diego), Flavio Schwarz(InterScience (United States)), Richard D. Wells(University of Washington), Sarah J. Dunstan(The University of Melbourne), Thomas J. Scriba(South African Tuberculosis Vaccine Initiative), Munyaradzi Musvosvi(South African Tuberculosis Vaccine Initiative), Maxine Caws(Liverpool School of Tropical Medicine), Glenna J. Peterson(University of Washington), Jerry J. Fong(University of California San Diego), Nguyen Thi Hoang(Oxford University Clinical Research Unit), Mark Hatherill(South African Tuberculosis Vaccine Initiative), Nguyen Duc Bang(Pham Ngoc Thach Hospital), Guy Thwaites(Oxford University Clinical Research Unit)
Cited by 20
Related Papers
Biological roles of oligosaccharides: all of the theories are correct
|Glycobiology|1993|5.2k
Essentials of Glycobiology
|Unknown|1999|2.5k
Siglecs and their roles in the immune system
|Nature reviews. Immunology|2007|2k
Symbol Nomenclature for Graphical Representations of Glycans
|Glycobiology|2015|1.1k